SMC recommends Eladynos for postmenopausal osteoporosis in Scotland
Ella Day | July 8, 2025 | News story | Medical Communications, Research and Development | Musculo-skeletal disorder, NHS, Scottish Medicine Consortium, Theramex, clinical trials, osteoporosis, postmenopause
Theramex, a women’s health pharma company, has announced that the Scottish Medicines Consortium has recommended Eladynos (abaloparatide) for NHS use in Scotland. This offers a new treatment option for postmenopausal women at high risk of fracture.
Osteoporosis is a progressive condition causing fragile bones and fractures. Hip fractures alone are responsible for around 50% of fracture-related deaths in women. Many patients remain undiagnosed or untreated, and fractures often recur before osteoporosis is identified.
Eladynos is an anabolic therapy and works by stimulating new bone formation to strengthen bones and reduce the risk of fracture. Clinical trials, including the ACTIVE and ACTIVExtend studies, showed significant reductions in vertebral fractures and consistent protection when followed by bisphosphonate therapy. It is a once-daily injection and recommended for up to 18 months of treatment.
Tina Backhouse, UK general manager at Theramex, stated: “With women at a five times greater risk of osteoporosis than men, I am thrilled that we are able to expand access further across the UK and bring this treatment to women in Scotland.”
The approval follows previous guidance from NICE and means that, for the first time, women in Scotland will have NHS access to this treatment. However, charities warn that gaps in care remain, with many high-risk patients still missing out on timely diagnosis and treatment.
Ella Day
8/7/25
Related Content
A community-first future: which pathways will get us there?
In the final Gateway to Local Adoption article of 2025, Visions4Health caught up with Julian …
Vesper Bio reports positive topline results for dementia candidate
Vesper Bio, a clinical-stage biotech developing novel oral therapies for neurodegenerative and neuropsychiatric disorders, has …
Von Willebrand disease – increasing awareness and access to vital care
Pharmafile talks to Anthea Cherednichenko, Vice President Franchise Head Haematology and Transplant at Takeda about …
